John Edwards, Executive Chair
John Edwards has over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at a series of successful biotechnology companies. Most recently he helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President. Earlier, John was VP Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, where he held senior-level positions in R&D, manufacturing, and commercial operations. Currently, John also serves as executive chairman of F-star. He started his career in R&D at Genzyme (pre-IPO). John received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the U. Massachusetts at Amherst.
Barbara S. Fox, PhD, CEO
Barbara Fox is the founding CEO of Tilos Therapeutics. She has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Barbara received her AB in chemistry from Bryn Mawr, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the NIH. She was an EY Entrepreneur of The Year™ 2014 Award finalist in New England.
Detlev Biniszkiewicz, PhD
Detlev Biniszkiewicz, Ph.D. is a Managing Director at MPM Capital where he is responsible for the identification and evaluation of new investment opportunities as well as providing operational and strategic guidance to the firm’s portfolio investments. Detlev is an experienced biopharma executive and brings deep knowledge of oncology and immuno-oncology to this role. Most recently, Detlev was the President and CEO of Surface Oncology (SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso® – two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical alliances, and academic collaborations. Detlev has also held multiple roles at Novartis including Global Head of Portfolio Management and Analysis, where his group provided oversight of Novartis’ research and early development portfolio. Detlev began his career as a Principal at the Boston Consulting Group (BCG) and performed his academic research with Dr. Rudolf Jaenisch at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA.
Martin Heidecker, PhD
Martin Heidecker joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, he established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. Prior to BIVF, Martin held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. He began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. Martin holds a PhD in Biology as well as a Master degree in Biology and Economics.
Roger Kitterman is Vice President, Venture and Managing Partner of the Partners Innovation Fund. In this role, he leads the Innovation Fund and Licensing teams. Roger also serves as Executive Director of the Boston Biomedical Innovation Center. He has been with the Partners Innovation Fund, a $140 million fund investing in Partners spinouts, since its launch in 2008. He is an experienced venture capital investor with more than 20 years in the industry and has guided multiple venture-backed companies through the earliest stages of development. He has also been the startup CEO for three venture-backed companies and is a founder of Mass Medical Angels. He has previously served as a partner at life science-focused venture funds in the Boston area. Roger began his venture capital career in Eastern Europe with the Bulgarian- American Enterprise Fund, a $55 million venture capital fund. Roger holds an MBA in Finance and Business Development from the Columbia Business School and an AB from Harvard College.
Jay Knowles has more than 20 years in the biotech / pharma industry and has guided multiple early stage companies through drug discovery and development. He was previously CEO of X-BODY Biosciences (sold to Juno), an emerging biotech focused on generating antibodies against GPCRs and ion channels. Prior to this, he was Head, Platforms, Strategic Alliances for Novartis, where he led a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. Jay was President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and onto the market. He was also Vice President, Business Development, at Novacea and at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.